enGene Therapeutics Inc.
ENGN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001980845
In the last 90 days, enGene Therapeutics Inc. insiders filed 1 open-market purchase and 0 sales; 60 institutions reported holding it in 13F filings for Q2 2026, worth $86.5M in total; no superinvestor holds it.
Other share classesENGNW
13F holders, Q3 2025
Institutional positions in enGene Therapeutics Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 37
- +1 vs. Q2 2025
- Shares held
- 40.9M
- +448.0K (+1.1%) vs. Q2 2025
- Total value
- $279.1M
- +$132.0M (+89.7%) vs. Q2 2025
- New holders
- 7
- 7 more added
- Sold out
- 6
- 8 more reduced
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ENGN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 60 | $86.5M |
| Q1 2026 | 62 | $383.0M |
| Q4 2025 | 58 | $530.8M |
| Q3 2025 | 37 | $279.1M |
| Q2 2025 | 36 | $147.1M |
| Q1 2025 | 31 | $183.4M |
| Q4 2024 | 34 | $274.7M |
| Q3 2024 | 30 | $227.7M |
| Q2 2024 | 30 | $307.1M |
| Q1 2024 | 31 | $536.1M |
| Q4 2023 | 11 | $130.9M |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding enGene Therapeutics Inc.; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FCPM III Services B.V. | 9,632,561 | $65.8M | 13.15% | 00.0% | Unchanged |
| VR Adviser, LLC | 5,046,414 | $34.5M | 1.94% | 00.0% | Unchanged |
| Kynam Capital Management, LP | 4,994,090 | $34.1M | 2.54% | 00.0% | Unchanged |
| Blue Owl Capital Holdings LP | 3,278,106 | $22.4M | 6.95% | −450,000−12.1% | Reduced |
| Cormorant Asset Management, LP | 2,323,595 | $15.9M | 1.10% | 00.0% | Unchanged |
| Braidwell LP | 2,266,319 | $15.5M | 0.46% | +2,266,319 | New |
| Deep Track Capital, LP | 2,239,353 | $15.3M | 0.43% | −2,318,222−50.9% | Reduced |
| Perceptive Advisors LLC | 2,097,236 | $14.3M | 0.41% | +2,097,236 | New |
| Point72 Asset Management, L.P. | 1,208,399 | $8.25M | 0.02% | +1000.0% | Added |
| Frazier Life Sciences Management, L.P. | 1,157,380 | $7.90M | 0.24% | +1,157,380 | New |
| Franklin Resources Inc | 1,038,000 | $7.09M | 0.00% | 00.0% | Unchanged |
| Adage Capital Partners GP, L.L.C. | 1,000,000 | $6.83M | 0.01% | 00.0% | Unchanged |
| Sr One Capital Management, LP | 747,750 | $5.11M | 0.74% | 00.0% | Unchanged |
| Bank of America Corp | 647,192 | $4.42M | 0.00% | −1,358,516−67.7% | Reduced |
| MPM Oncology Impact Management LP | 530,299 | $3.62M | 0.59% | +530,299 | New |
| Omega Fund Management, LLC | 526,357 | $3.60M | 1.62% | 00.0% | Unchanged |
| Sphera Funds Management Ltd. | 504,409 | $3.45M | 0.82% | 00.0% | Unchanged |
| Morgan Stanley | 435,291 | $2.97M | 0.00% | +82,523+23.4% | Added |
| Vestal Point Capital, LP | 370,000 | $2.53M | 0.11% | 00.0% | Unchanged |
| Marshall Wace, LLP | 343,928 | $2.35M | 0.00% | 00.0% | Unchanged |
| Goldman Sachs Group Inc | 147,602 | $1.01M | 0.00% | −751,484−83.6% | Reduced |
| Affinity Asset Advisors, LLC | 77,000 | $525.9K | 0.05% | 00.0% | Unchanged |
| Citadel Advisors LLC | 58,370 | $398.7K | 0.00% | +35,327+153.3% | Added |
| Northern Trust Corp | 30,295 | $206.9K | 0.00% | −2,731−8.3% | Reduced |
| Geode Capital Management, LLC | 29,018 | $198.2K | 0.00% | 00.0% | Unchanged |
| Schonfeld Strategic Advisors LLC | 25,070 | $171.2K | 0.00% | −149,500−85.6% | Reduced |
| Millennium Management LLC | 20,502 | $140.0K | 0.00% | +7,472+57.3% | Added |
| Wells Fargo & Company | 17,910 | $122.3K | 0.00% | +14,711+459.9% | Added |
| Pale Fire Capital SE | 17,254 | $117.8K | 0.01% | 00.0% | Unchanged |
| Hudson Bay Capital Management LP | 11,074 | $75.6K | 0.00% | +11,074 | New |
| Toronto Dominion Bank | 10,000 | $68.3K | 0.00% | −4,537−31.2% | Reduced |
| Raymond James Financial Inc | 10,000 | $68.3K | 0.00% | +7,932+383.6% | Added |
| PFS Partners, LLC | 9,000 | $61.5K | 0.03% | +9,000 | New |
| Royal Bank of Canada | 7,915 | $54.0K | 0.00% | 00.0% | Unchanged |
| MAI Capital Management | 776 | $5.30K | 0.00% | −2,149−73.5% | Reduced |
| SBI Securities Co., Ltd. | 31 | $212 | 0.00% | +1+3.3% | Added |
| Citigroup Inc | 1 | $7 | 0.00% | +1 | New |
| OrbiMed Advisors LLC | 0 | $0 | 0.00% | −677,977−100.0% | Sold out |
| ADAR1 Capital Management, LLC | 0 | $0 | 0.00% | −27,787−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −11,400−100.0% | Sold out |
| Paloma Partners Management Co | 0 | $0 | 0.00% | −10,319−100.0% | Sold out |
| Wolverine Asset Management LLC | 0 | $0 | 0.00% | −6,361−100.0% | Sold out |
| NBC Securities, Inc. | 0 | $0 | 0.00% | −380−100.0% | Sold out |